feed
view company updates
tools
perform investment research
network
join events & discussions
advisory
about us
Redeye Capital
Egetis Therapeutics: A short-cut to the market
Research Note
2022-01-18
12:17
Redeye comments on the revised regulatory strategy for marketing authorization for Emcitate, announced by Egetis this morning.
KS
Kevin Sule
Disclosures and disclaimers
Premium Plan required to unlock
Unlock companies to access
more high quality research.
View Plans